Previously, Shaalan Beg et al. have conducted a clinical trial and as a result, explored a novel Nqo1 bioactivatable drug, named as ARQ761, to target pancreatic cancer treatment and to improve the chemotherapeutic impacts by metabolic modulation in pancreatic cancer [108]. This evidence concerns the gene NQO1 and pancreatic neoplasm.